Abstract
Intramyocellular lipid (IMCL) accumulation has been linked to both insulin-resistant and insulin-sensitive (athletes) states. Biochemical analysis of intramuscular triglyceride composition is confounded by extramyocellular triglycerides in biopsy samples, and hence the specific composition of IMCLs is unknown in these states. 1H magnetic resonance spectroscopy (MRS) can be used to overcome this problem. Thus, we used a recently validated 1H MRS method to compare the compositional saturation index (CH2:CH3) and concentration independent of the composition (CH3) of IMCLs in the soleus and tibialis anterior muscles of 16 female insulin-resistant lipodystrophic subjects with that of age- and gender-matched athletes (n = 14) and healthy controls (n = 41). The IMCL CH2:CH3 ratio was significantly higher in both muscles of the lipodystrophic subjects compared with controls but was similar in athletes and controls. IMCL CH2:CH3 was dependent on the IMCL concentration in the controls and, after adjusting the compositional index for quantity (CH2:CH3adj), could distinguish lipodystrophics from athletes. This CH2:CH3adj marker had a stronger relationship with insulin resistance than IMCL concentration alone and was inversely related to VO2max. The association of insulin resistance with the accumulation of saturated IMCLs is consistent with a potential pathogenic role for saturated fat and the reported benefits of exercise and diet in insulin-resistant states.
Keywords: triglycerides, fatty acids, lipodystrophies, spectroscopy, lipid composition, muscle, exercise, in vivo
After it was demonstrated that 1H magnetic resonance spectroscopy (MRS) can noninvasively distinguish intramyocellular lipids (IMCLs) from extramyocellular lipids (EMCLs) (1, 2), associations were reported between soleus (SOL) IMCL accumulation and insulin resistance independent of fat mass (3–5). Given that skeletal muscle represents the primary site for postprandial glucose disposal (6), these findings were of considerable physiological interest. Furthermore, these data strongly supported the link between ectopic fat accumulation and insulin resistance (7, 8). Although it soon became clear that triglycerides themselves were unlikely to be involved in causing insulin resistance, intramuscular triglyceride content does seem to correlate with insulin resistance in some states (5, 9–12). One particularly striking and surprising exception was reported in athletes, in which histological studies suggested that neutral lipid accumulation was a feature of skeletal muscle in insulin-sensitive, endurance-trained athletes (13, 14), and this finding has led to the now widely cited notion of an “athlete’s paradox” (13). This concept is consistent with the idea that triglyceride content itself is not casually involved in insulin resistance and has prompted several efforts to identify the lipid intermediates responsible for causing insulin resistance or preserving the insulin sensitivity of athletes.
Saturated fat has been implicated in the pathogenesis of metabolic disease (15, 16), and we have recently described and validated (using IMCL/EMCL-simulated phantoms of known composition) a 1H MRS method that provides an in vivo compositional marker of IMCLs that primarily reflects the degree of saturation of the FA chains within triglycerides (17). This marker, which we call the IMCL saturation index (CH2:CH3), utilizes good-quality spectra acquired at 3T with a short echo time and compares the CH2 resonance located at 1.3 ppm (which is influenced by both concentration and composition) with that of the CH3 resonance at 0.9 ppm (which is independent of triglyceride composition); this is illustrated in Fig. 1 . Figure 1 also shows that using a concentration of hydrogen that resonates at 1.3 ppm (CH2) to represent the concentration of lipids without knowing the underlying composition, as has been the practice in virtually all published 1H MRS studies of IMCLs so far, confounds the contributions of both the concentration of lipids and their composition. This can potentially lead to a significant error in estimating the concentration: the composition would contribute as much as 50% to the observed signal (equivalent to a 100% theoretical increase in the signal) if the pool were stearic acid instead of linoleic acid. Therefore, we used the IMCL CH3 peak at 0.9 ppm to estimate the total concentration of IMCLs, as this is independent of the degree of saturation of the FA chains within triglycerides (i.e., composition). We call this the composition-independent IMCL concentration estimate to distinguish it from the conventional estimate using CH2.
Lipodystrophy is a rare cause of severe insulin resistance and is typically characterized by prominent ectopic fat accumulation due to both the reduction in adipocyte lipid storage capacity and the associated hyperphagia induced by leptin deficiency. To ascertain whether IMCL composition is altered in lipodystrophic (LD) subjects and if such changes in lipid composition might help to elucidate the athlete’s paradox, we determined the compositional saturation index (CH2:CH3 ratio) and composition-independent concentration (from CH3) of IMCLs in the SOL and tibialis anterior (TA) muscles of female insulin-resistant LD subjects as well as age- and gender-matched athletes and nonathlete controls.
MATERIALS AND METHODS
Participants
Sixteen female subjects with lipodystrophy were identified as part of a long-standing study of human insulin-resistant syndromes, while age- and gender-matched controls (n = 41) and athletes (n = 14) were recruited by advertisement. SOL IMCL data from five of the subjects were included in a previously published study (18). Control and athlete exclusion criteria included current smoking; drug or alcohol addiction; any current or past medical disorder or medications that could affect measurements, including supplements such as creatine; and standard MRI contraindications. Controls were recruited who exercised less than three times per week for 1 h each time, while the athletes, some of whom competed in international events, were part of a running club and regularly ran distances between 10 and 40 km. Subjects with lipodystrophy were recruited if they could perform an overnight fast without insulin or a rapid-acting insulin analogue. The studies relating to lipodystrophy were approved by the NHS Research Ethics Committee, and the healthy volunteer studies were approved by the East of England Cambridge Central Ethics Committee. Studies were conducted in accordance with the Declaration of Helsinki, and all participants provided written informed consent.
Protocol
Volunteers were instructed to follow normal dietary habits for 3 days before arriving at the National Institute for Health Research (NIHR)/Wellcome Trust Clinical Research Facility. Participants provided fasting blood samples and were given a light breakfast of either toast or cereal immediately prior to 1H MRS. Athletes and controls were instructed to refrain from vigorous exercise for at least 24 and 19 h, respectively, prior to 1H MRS.
HOMA-IR was calculated as fasting insulin (pmol/l) × fasting glucose (μU/ml)/22.5. Body composition was assessed by dual-energy X-ray absorptiometry (Lunar Prodigy enCORE version 12.5 for controls and Lunar iDXA enCORE version 16 for athletes; GE Healthcare, Madison, WI).
1H MRS
1H MRS studies were performed on a 3T scanner (Siemens; Erlangen, Germany) using the point-resolved spectroscopy sequence with a short echo time of 35 ms. A water-suppressed 1H spectrum was acquired from a voxel with a cube length of 1.3 cm positioned to avoid visible fat on T1-weighted images within TA and SOL using a 5 s repetition time and 64 averages (4 averages for the nonwater-suppressed spectrum). Data were analyzed in jMRUI (19, 20) and fitted with the AMARES (21) algorithm using identical prior-knowledge parameters: Gaussian line shapes (except water: Lorentzian), soft constraints on EMCL/IMCL CH2 frequencies and line widths, CH3 resonant frequencies and line widths determined from known and inferred prior knowledge relative to the CH2 resonance (22), and with all amplitudes estimated. Because the CH3 resonance is small and may be subject to spectral overlap, the results were later checked for robustness by reanalyzing the data using different fitting parameters, as outlined in supplemental Table S1. IMCL CH2 and CH3 are quantified relative to the methyl group of creatine plus phosphocreatine at 3.0 ppm. Because this resonance exhibits different line-shape characteristics in the TA and SOL muscles (23), comparable quantification between muscles using a nominal concentration of muscle creatine is not valid; instead, a scaling factor of creatine to water for each muscle was established from a subset of participants who had nonwater-suppressed data sets, yielding a calculated water signal. Absolute composition-independent IMCL concentrations in mmol/kg muscle wet weight were calculated from the compositionally invariant CH3 IMCL resonance, with standard assumptions regarding muscle water content and correction for T2 relaxation effects, J coupling, and proton density as outlined below.
Absolute IMCL concentrations in mmol/kg muscle wet weight were calculated using the CH3 IMCL resonance (which is compositionally invariant) using the following equation:
where S o is the corrected signal intensity of the resonance, water-calc is the calculated water signal from the internal standard (creatine and phosphocreatine), and [water] is the concentration of water in skeletal muscle [calculated using a pure water concentration of 55,342 mmol/l and assuming a relative tissue water content in human skeletal muscle of 0.81 (kg/kg) and tissue density of 1.05 g/ml (24)]. Because the IMCL CH3 resonance is subject to J-coupling effects and has an unknown T2 relaxation time, we utilized the theoretical-to-measured IMCL CH3:CH2 ratio that would take into effect both J-coupling and T2 effects at this echo time as well as any bias of constrained fitting prior knowledge of the CH3 resonance.
Therefore,
where S is the uncorrected signal intensity of the resonance. (G TM CH3:CH2) = 1.1966 and is the gradient of the line of best fit through the origin of the graph of theoretical-to-measured CH3:CH2 in vitro in IMCL- and EMCL-simulated phantoms using the point-resolved spectroscopy sequence at 3T with an echo time of 35 ms with the same fitting (17), assuming that J-coupling and T2 relaxation effects would be similar in vivo. (T 2corr CH2/water) is the correction factor for T2 effects of CH2 and water that was calculated using accepted T2 values at 3T for each muscle (25), and (n water:IMCL CH3) is the correction for proton density.
The IMCL saturation index (CH2:CH3) was calculated as IMCL CH2:CH3, and the IMCL saturation index adjusted for quantity (CH2:CH3adj) = CH2 – (mCH3 + c), where m and c are the gradient and intercept, respectively, of the regression line through the control data points of CH2 versus CH3. Investigators were blind to the insulin-resistance status of the participants during 1H MRS analysis.
Assessment of VO2max
Participants underwent continuous incremental exercise testing to an 85% age-predicted maximum heart rate (controls) or volitional exhaustion (athletes) on a Trackmaster TMX425 treadmill (Med-Electronics, Beltsville, MD). LD subjects did not perform an exercise test. Oxygen consumption was measured using a spiroergometer (Medical Graphics UK Ltd, Gloucester, UK) and BreezeSuite gas-exchange software. For the control participants, a standard incremental protocol was performed (26), whereas the athletes undertook a protocol that began with a 10 min warm-up period at each participant’s preferred warm-up running speed, after which the test was initiated at 9 km/h and increased steadily (0.74 km/h/min), with a ramp at 5 min (increasing 0.5% every 15 s) until exhaustion or a plateau in VO2 was apparent. VO2max was calculated in the control participants by extrapolating the submaximal heart rate – VO2 relationship to the age-predicted maximum heart rate (27).
Statistics
All statistics were performed in SPSS Statistics 24 (IBM, Armonk, NY) with significance set at P < 0.05. Normality was assessed by the Shapiro-Wilk test, and nonnormally distributed data were log-transformed prior to statistical testing. ANOVA with Games-Howell post hoc analysis was used to compare means between groups, and Pearson’s correlation coefficient was used for analyzing associations. Due to the nonnormality of ln(HOMA-IR), IMCL associations with HOMA-IR were assessed by Spearman’s rank correlation coefficient. Data are presented as means ± SEMs.
RESULTS
Participants
Of the insulin-resistant subjects with lipodystrophy, 13 had partial forms [8 subjects with familial partial lipodystrophy (FPLD) type 2 due to LMNA mutations, 5 subjects with FPLD3 due to PPARG mutations), and 3 had generalized lipodystrophy [2 subjects with acquired generalized lipodystrophy (AGLD) and 1 due to mutations in the PCYT1A gene (28)]. Of the LD subjects, two were taking no medication at all, eight were prescribed metformin, three were taking statins, five were taking fibrates, and five were taking long-acting insulin analogues. The age- and gender-matched controls had a wide BMI range (19.6–35.6 kg/m2) and HOMA-IR (0.3–4.9). As a group, insulin and HOMA-IR were significantly higher in the LD subjects and lower in the athletes ( Table 1 ) compared with controls, as expected. Fat mass and percentage body fat were similar between LD subjects and athletes, which were both lower compared with controls (Table 1). Serum triglycerides were higher and HDL-cholesterol concentrations were lower in the LD subjects (Table 1) compared with either controls or athletes. EMCLs were absent in the two subjects with AGLD ( Fig. 2 ), but those with partial forms of lipodystrophy had an EMCL concentration such that overall LD subjects’ EMCL concentration was similar to both controls and athletes (Table 1).
TABLE 1.
LD Females (n = 16) | Female Controls (n = 41) | Female Athletes (n = 14) | P | ||||
ANOVA | LD—Controls | LD—Athletes | Controls—Athletes | ||||
Participant characteristics | |||||||
Age (years) | 38.9 ± 3.9 | 35.5 ± 2.0 | 36.5 ± 2.9 | 0.694 | |||
BMI (kg/m2) | 24.2 ± 0.7 | 24.4 ± 0.6 | 20.3 ± 0.6 | <0.001 | 0.999 | 0.001 | <0.001 |
Mass (kg) | 66.1 ± 2.8 | 65.2 ± 2.3 | 54.6 ± 1.3 | 0.013 | 0.916 | 0.006 | 0.001 |
Fat mass (kg) | 10.6 ± 1.4 | 23.1 ± 1.6 | 11.6 ± 1.1 | <0.001 | 0.001 | 0.631 | <0.001 |
Fat-free mass (kg) | 55.4 ± 1.7 | 42.1 ± 0.9 | 43.0 ± 1.2 | <0.001 | <0.001 | <0.001 | 0.705 |
Body fat (%) | 16.1 ± 1.7 | 34.2 ± 1.2 | 21.1 ± 1.8 | <0.001 | <0.001 | 0.129 | <0.001 |
Triglycerides (mmol/l) | 3.54 ± 0.67 | 0.92 ± 0.07 a | 0.84 ± 0.08 | <0.001 | <0.001 | <0.001 | 0.920 |
HDL-cholesterol (mmol/l) | 0.97 ± 0.71 | 1.64 ± 0.06 a | 2.20 ± 0.12 | <0.001 | <0.001 | <0.001 | 0.001 |
Glucose (mmol/l) | 6.00 ± 0.58 | 4.56 ± 0.06 a | 4.46 ± 0.13 | <0.001 | 0.063 | 0.002 | 0.764 |
Insulin (pmol/l) b | 145.6 ± 22.0 | 38.6 ± 4.2 a | 22.6 ± 4.7 | <0.001 | <0.001 | <0.001 | 0.025 |
HOMA-IR | 5.53 ± 1.0 | 1.14 ± 0.13 a | 0.66 ± 0.15 | <0.001 | <0.001 | <0.001 | 0.025 |
HbA1c (%) | 6.6 ± 0.4 c | ND | 5.3 ± 0.1 | ND | 0.008 | ||
VO2max (ml/kg/min) | ND | 36.1 ± 1.5 d | 46.9 ± 1.4 | ND | <0.001 | ||
Conventional estimates e | |||||||
SOL IMCLs | 1.90 ± 0.21 | 1.22 ± 0.07 | 0.79 ± 0.10 | <0.001 | 0.027 | <0.001 | 0.007 |
TA IMCLs | 0.89 ± 0.16 f | 0.61 ± 0.04 | 0.45 ± 0.04 | 0.035 | 0.562 | 0.115 | 0.078 |
SOL EMCLs | 2.05 ± 0.34 | 2.22 ± 0.19 | 1.81 ± 0.20 | 0.493 | |||
TA EMCLs | 1.43 ± 0.28 f | 2.30 ± 0.19 | 1.24 ± 0.15 | 0.002 | 0.163 | 0.785 | 0.005 |
Data are presented as mean ± SEM unless otherwise stated. Nonnormally distributed variables were log-transformed prior to performing ANOVA and Games-Howell post hoc analysis; bold P values are statistically significant.
n = 38.
To convert to μU/ml divide by 6.945.
n = 13.
n = 24.
Expressed as methylene protons resonating at 1.3 ppm quantified as a percentage of the uncorrected calculated water resonance.
n = 12.
1H MRS analysis of IMCL concentration
In the SOL muscle, IMCL concentrations derived from the IMCL CH3 peak (0.9 ppm) (composition-independent IMCL concentrations) were not significantly increased (P = 0.477) in the LD subjects compared with controls but were higher compared with the lean athletes (P = 0.003) ( Fig. 3A ). In the more glycolytic TA muscle, composition-independent IMCL concentrations were similar in all three groups (Fig. 3B). We also observed linear inverse correlations of VO2max and the IMCL concentration in the subset of controls who underwent VO2max testing and athletes together (Fig. 3C, D). SOL IMCL concentration was significantly lower in the athletes compared with the controls (P = 0.004; Fig. 3A), and this remained significant (P = 0.025) compared with a subset of the controls matched for percentage body fat (controls: body fat = 21.5 ± 2.3%, n = 10; athletes: 21.1 ± 1.8%, n = 14; see supplemental Fig. S1).
The conventional estimate of IMCL concentration using the CH2 resonance uncorrected for composition, CH2/water, showed similar trends to the composition-independent estimate using the CH3 peak with the exception that the LD subjects’ SOL IMCL CH2 was significantly increased compared with controls (Table 1). This could be regarded as an artifact of the effects of compositional differences, which we consider next.
1H MRS analysis of IMCL composition
IMCLs had a significantly higher saturation index (CH2:CH3) in both muscles of the LD subjects compared with controls (SOL P = 0.008; TA P = 0.024) but not athletes ( Fig. 4A, B). In the control group, smaller IMCL pools were associated with a higher saturation index, as shown by the linear regression line (dotted line in Fig. 3E, F) having a gradient (ΔCH2/ΔCH3) that was less than the mean CH2:CH3 (e.g., gradient SOL = 6.7 vs. mean CH2:CH3 = 8.8; gradient TA = 4.2 vs. mean CH2:CH3 = 6.0). This phenomenon seemed to be independent of insulin sensitivity in the controls ( Table 2 ; there was no relation of HOMA-IR with IMCL concentration). To generate a pathophysiologically meaningful measure of composition that is independent of IMCL quantity, the vertical (CH2) deviation from this regression line was measured and taken as a marker of the saturation of the pool that is adjusted for quantity, which we term the adjusted saturation index (CH2:CH3adj). This adjusted compositional marker was significantly higher in LD subjects compared with athletes (SOL P = 0.001; TA P = 0.046) and controls (SOL P = 0.003), with a tendency in the TA that falls just short of conventional statistical significance (P = 0.06) (Fig. 4C, D).
TABLE 2.
IMCL Measure | HOMA-IR | |||
Controls (n = 38) | Controls and Athletes (n = 52) | Controls and LD Subjects (n = 54) a | Controls, LD Subjects, and Athletes (n = 68) b | |
SOL | ||||
Concentration (CH3) | −0.016 | 0.248 | 0.149 | 0.312* |
Concentration and composition (CH2) | 0.153 | 0.315* | 0.394** | 0.477*** |
Composition (CH2:CH3) | 0.217 | −0.048 | 0.439*** | 0.241* |
Composition adjusted for quantity (CH2:CH3adj) | 0.320* | 0.271* | 0.583*** | 0.532*** |
TA | ||||
Concentration (CH3) | 0.200 | 0.251 | 0.205 | 0.258* |
Concentration and composition (CH2) | 0.224 | 0.247 | 0.338* | 0.344** |
Composition (CH2:CH3) | 0.100 | −0.046 | 0.337* | 0.202 |
Composition adjusted for quantity (CH2:CH3adj) | 0.218 | 0.127 | 0.445*** | 0.364** |
*P < 0.05, **P < 0.01, and ***P ≤ 0.001.
n = 50 for TA.
n = 64 for TA.
Unlike the uncorrected measure of composition, this adjusted composition also had a significant relation to VO2max (Fig. 4E, F) within the control subset alone, athletes alone (SOL), and control and athletes combined, such that fitter individuals had less saturated IMCLs for the same absolute quantity of IMCLs. VO2max was significantly correlated with HOMA-IR in the control subset (r = −0.59, P = 0.003, n = 23) and in controls and athletes together (r = −0.53, P = 0.001, n = 37). Figure 4G and H show the relation of the adjusted composition to HOMA-IR. Table 2 shows relations of IMCL concentration and composition with insulin sensitivity. The saturation index was higher in the SOL muscle compared with the TA in all three groups. This was still the case in the two EMCL-deficient AGLD subjects (subject 1: SOL CH2:CH3 = 9.5 and TA CH2:CH3 = 6.3; subject 2: SOL CH2:CH3 = 11.2 and TA CH2:CH3 = 7.1). The IMCL relations with HOMA-IR were robust to differing fitting parameters, as shown in supplemental Table S1.
DISCUSSION
Using a recently validated 1H MRS method we compared a compositional saturation index (CH2:CH3 ratio) of IMCLs in the SOL and TA muscles of female insulin-resistant LD subjects with that of age- and gender-matched athletes and healthy controls and showed it to be significantly higher in both muscles compared with controls but not athletes. The finding that smaller IMCL pools in the control group had a relatively higher saturation index than larger pools irrespective of insulin sensitivity could possibly explain why the athletes studied here, who had small IMCL pools, had a composition that was statistically similar to LD subjects. This observed concentration-composition relationship seems physiologically plausible given that more unsaturated and shorter-chain FAs are preferentially mobilized (17). A similar trend was also visible in a previous data set from both TA and SOL muscles of 19 healthy males after an 8 h fast (17). We hypothesize that a person may “move” along a line such as this while performing daily activities and that a measurement of deviation from this relationship may therefore be a more sensitive and specific measure of muscle metabolic physiology or pathophysiology. To take this concentration-composition dependence into consideration we adjusted the compositional saturation index for concentration (CH2:CH3adj), and this marker was able to distinguish between athletes and LD subjects in both muscles. The strong inverse relation of CH2:CH3adj with VO2max indicates that fitness is associated with a relatively lower saturation of IMCLs, although overall athletes and controls were not statistically different; this is similar to results from a biopsy study (29) that demonstrated a comparable percentage of saturated intramuscular triglycerides in male controls and athletes. Interestingly, previous reports of intramuscular triglyceride composition in insulin-resistant states (30, 31) yielded no difference in saturation percentage but did reveal a difference in linoleate (31). In these studies, the intramuscular triglyceride content was higher in insulin-resistant states; therefore, a higher saturation percentage may not be apparent given the composition-concentration relation we found. This lack of a difference in saturation could also equally be explained by the difference in sampling intramuscular versus intramyocellular pools, as EMCLs generally make up a significant proportion of intramuscular triglycerides (approximately twice the IMCL pool in our healthy cohorts even when voxels were placed to avoid visible marbling on T1-weighted images; Table 1).
By our measure of composition-independent IMCLs (using the CH3 instead of the uncorrected CH2 resonance), we found that the LD subjects’ IMCL concentration was not significantly higher in either muscle compared with age-, gender-, and BMI-matched controls but was higher in the SOL relative to athletes. There are few reports of IMCLs in LD subjects, but our findings are in agreement with Peterson et al. (32), who in three subjects with generalized lipodystrophy (two congenital and one acquired) found SOL IMCL concentrations that were similar to six age-, BMI-, and weight-matched controls. Calf IMCL concentration was also lower in a case report of acquired generalized lipodystrophy (33) compared with controls, while a study of four subjects with congenital generalized lipodystrophy suggested that IMCL concentration was higher (24). Using the CH2 resonance, as has been conventional in previous studies, we found SOL IMCL content to be significantly higher in our LD subjects compared with controls (Table 1), demonstrating, we argue, the influence of composition on measures of concentration.
The athlete’s paradox
We found that the athletes’ IMCL concentration was significantly lower (SOL) or similar (TA) to controls. Although this seems to contradict well-known reports of an athlete’s paradox using both biopsy methods (13, 29, 34–36) and 1H MRS (37, 38), this finding is in agreement with studies that reported no such paradox compared with old or young controls (39), obese individuals (40), or in certain fiber types (14). It is known that athletes can have a large depletion-repletion range of IMCLs, and it is possible that the IMCL concentration had not fully recovered since the last training session (24–48 h prior), as IMCLs can still increase significantly after these intervals (41). In fact, our results demonstrate an inverse relation of IMCL content and VO2max that is consistent with a study by Boesch et al. (42), in which a combination of daily training at 60% of the VO2 peak with a low-fat (10% to 15% fat) diet depleted IMCL levels in both the vastus lateralis and TA muscles to a consistent level that correlated with the VO2 peak, suggesting that our elite female athletes were nearly “empty” of IMCLs; we did not control for diet in our study.
Relationship of whole-body insulin resistance to IMCLs
Within the controls, only the compositional saturation index adjusted for quantity (CH2:CH3adj) in the SOL was significantly correlated with whole-body insulin resistance (Table 2). The inclusion of insulin-resistant LD subjects increases the statistical significance of this relation and yields associations with other composition-influenced markers, but not IMCL concentration, in either muscle. In our study, the addition of athletes predictively reduced the associations with composition, as their pools were small and therefore had a tendency for a higher saturation index, but relations remained with measures that reflect large saturated pools (i.e., CH2:CH3adj and CH2). These striking results suggest that the accumulation of saturated IMCLs and not concentration alone relates to early-stage insulin resistance.
Supporting our findings, the concentration of the most abundant saturated fat, palmitic acid, within muscle triglycerides has been shown to be related to insulin sensitivity (43). Palmitic acid is known to increase ceramide concentrations, which are thought to engage stress-responsive serine kinases that impede insulin activation of its cell-surface receptor, as well as downstream signaling molecules such as insulin receptor substrate 1 and protein kinase B/Akt (44). Our study was of course not able to probe these mechanisms.
Limitations
Unlike previous 1H MRS studies that have conventionally reported IMCL concentrations using the predominant CH2 resonance while assuming a notional normal composition, here we utilized the smaller CH3 resonance, which has the advantage of composition independence and, with comprehensive prior-knowledge constraints, including line-width constraints relative to the CH2 resonance (22), fitted the IMCL CH3 resonance from the overlapping EMCL/IMCL CH3 signals. Due to fiber-orientation differences between the SOL and TA muscles, the EMCL resonances are very slightly systematically shifted between muscle groups. Despite this potential for a systematic difference in the CH2:CH3 ratio between muscles, this ratio was still higher in the SOL compared with the TA muscle in both EMCL-deficient AGLD subjects, consistent with findings in our other participants in this study and a previous study (17) suggesting a compositional difference between muscles. Our LD subjects, who mainly had partial forms of lipodystrophy, had overall similar quantities of EMCLs to those of our controls and athletes that has helped to reduce potential intergroup influence of this overlapping resonance. In addition, the relations of IMCLs with HOMA-IR were robust to differing fitting routines, including constraining the EMCL CH3 amplitude and accounting for asymmetric line shapes. These findings, together with the finding that neither the IMCL CH2:CH3 nor IMCL CH2:CH3adj markers related to either EMCL CH2 or CH3, suggests a lack of EMCL influence in our data sets; however, it is possible that in other insulin-resistant cohorts large overlapping EMCL resonances may be a confounding factor.
Summary
The use of our recently validated and potentially widely applicable 1H MRS approach to determine both the IMCL composition and concentration independent of composition within the SOL and TA muscles of female individuals covering a wide range of insulin sensitivities has revealed that markers of the accumulation of saturated triglycerides in the IMCL pool are more strongly associated with whole-body insulin resistance than IMCL concentration alone. Differences in associations of insulin resistance with IMCL concentration when using the CH3 and conventional CH2 peaks for quantification highlights the need for awareness of the potential influence of composition on previously reported 1H MRS measures of concentration.
Our finding of a strong relationship between VO2max and relatively unsaturated IMCL pools in controls and athletes points to a role of exercise in decreasing the amount of saturated fat within the IMCL store. The association of insulin resistance with the accumulation of saturated IMCLs, even within a healthy control population, could suggest an early involvement in its pathogenesis and provide a reason why combined exercise and diet are effective therapeutic options in the early stages of insulin resistance.
Supplementary Material
Acknowledgments
The authors thank the participants and staff at both the NIHR/Wellcome Trust Cambridge Clinical Research Facility and the Wolfson Brain Imaging Centre. The authors also thank the NIHR Core Biochemistry Assay Laboratory, Cambridge Biomedical Research Centre, for providing the insulin analysis and Wiktor Olszowy for statistical advice.
Footnotes
Abbreviations:
- AGLD
- acquired generalized lipodystrophy
- EMCL
- extramyocellular lipid
- FPLD
- familial partial lipodystrophy
- HOMA-IR
- Homeostatic Model Assessment of Insulin Resistance
- IMCL
- intramyocellular lipid
- LD
- lipodystrophic
- MRS
- magnetic resonance spectroscopy
- NIHR
- National Institute for Health Research
- SOL
- soleus
- TA
- tibialis anterior
This work was supported by grants from the UK National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre; the UK Medical Research Council Centre for Obesity and Related Metabolic Diseases; the Clinical Research Infrastructure Grant; and Wellcome Trust Grant 107064 (D.B.S.). A.S. was supported by the NIHR via an award to the NIHR Cambridge Clinical Research Facility. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or Department of Health and Social Care.
The online version of this article (available at http://www.jlr.org) contains a supplement.
REFERENCES
- 1. Schick F., Eismann B., Jung W-I., Bongers H., Bunse M., and Lutz O.. 1993. Comparison of localized proton NMR signals of skeletal muscle and fat tissue in vivo: two lipid compartments in muscle tissue. Magn. Reson. Med. 29: 158–167. [DOI] [PubMed] [Google Scholar]
- 2. Boesch C., Slotboom J., Hoppeler H., and Kreis R.. 1997. In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy. Magn. Reson. Med. 37: 484–493. [DOI] [PubMed] [Google Scholar]
- 3. Perseghin G., Scifo P., De Cobelli F., Pagliato E., Battezzati A., Arcelloni C., Vanzulli A., Testolin G., Pozza G., Del Maschio A., et al. . 1999. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes. 48: 1600–1606. [DOI] [PubMed] [Google Scholar]
- 4. Jacob S., Machann J., Rett K., Brechtel K., Volk A., Renn W., Maerker E., Matthaei S., Schick F., Claussen C. D., et al. . 1999. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes. 48: 1113–1119. [DOI] [PubMed] [Google Scholar]
- 5. Krssak M., Falk Petersen K., Dresner A., DiPietro L., Vogel S. M., Rothman D. L., Shulman G. I., and Roden M.. 1999. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia. 42: 113–116. [DOI] [PubMed] [Google Scholar]
- 6. Shulman G. I., Rothman D. L., Jue T., Stein P., DeFronzo R. A., and Shulman R. G.. 1990. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N. Engl. J. Med. 322: 223–228. [DOI] [PubMed] [Google Scholar]
- 7. Petersen K. F., and Shulman G. I.. 2002. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am. J. Cardiol. 90: 11–18. [DOI] [PubMed] [Google Scholar]
- 8. Savage D. B., Petersen K. F., and Shulman G. I.. 2005. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension. 45: 828–833. [DOI] [PubMed] [Google Scholar]
- 9. Sinha R., Dufour S., Petersen K. F., LeBon V., Enoksson S., Ma Y-Z., Savoye M., Rothman D. L., Shulman G. I., and Caprio S.. 2002. Assessment of skeletal muscle triglyceride content by 1H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes. 51: 1022–1027. [DOI] [PubMed] [Google Scholar]
- 10. Phillips D. I. W., Caddy S., Ilic V., Fielding B. A., Frayn K. N., Borthwick A. C., and Taylor R.. 1996. Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism. 45: 947–950. [DOI] [PubMed] [Google Scholar]
- 11. Pan D. A., Lillioja S., Kriketos A. D., Milner M. R., Baur L. A., Bogardus C., Jenkins A. B., and Storlien L. H.. 1997. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 46: 983–988. [DOI] [PubMed] [Google Scholar]
- 12. Forouhi N. G., Jenkinson G., Thomas E. L., Mullick S., Mierisova S., Bhonsle U., McKeigue P. M., and Bell J. D.. 1999. Relation of triglyceride stores in skeletal muscle cells to central obesity and insulin sensitivity in European and South Asian men. Diabetologia. 42: 932–935. [DOI] [PubMed] [Google Scholar]
- 13. Goodpaster B. H., He J., Watkins S., and Kelley D. E.. 2001. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J. Clin. Endocrinol. Metab. 86: 5755–5761. [DOI] [PubMed] [Google Scholar]
- 14. van Loon L. J. C., Koopman R., Manders R., van der Weegen W., van Kranenburg G. P., and Keizer H. A.. 2004. Intramyocellular lipid content in type 2 diabetes patients compared with overweight sedentary men and highly trained endurance athletes. Am. J. Physiol. Endocrinol. Metab. 287: E558–E565. [DOI] [PubMed] [Google Scholar]
- 15. Hernández E. Á., Kahl S., Seelig A., Begovatz P., Irmler M., Kupriyanova Y., Nowotny B., Nowotny P., Herder C., Barosa C., et al. . 2017. Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance. J. Clin. Invest. 127: 695–708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Luukkonen P. K., Sädevirta S., Zhou Y., Kayser B., Ali A., Ahonen L., Lallukka S., Pelloux V., Gaggini M., Jian C., et al. . 2018. Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars. Diabetes Care. 41: 1732–1739. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Thankamony A., Kemp G. J., Koulman A., Bokii V., Savage D. B., Boesch C., Hodson L., Dunger D. B., and Sleigh A.. 2018. Compositional marker in vivo reveals intramyocellular lipid turnover during fasting-induced lipolysis. Sci. Rep. 8: 2750. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Sleigh A., Stears A., Thackray K., Watson L., Gambineri A., Nag S., Campi V. I., Schoenmakers N., Brage S., Carpenter T. A., et al. . 2012. Mitochondrial oxidative phosphorylation is impaired in patients with congenital lipodystrophy. J. Clin. Endocrinol. Metab. 97: E438–E442. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Naressi A., Couturier C., Devos J. M., Janssen M., Mangeat C., de Beer R., and Graveron-Demilly D.. 2001. Java-based graphical user interface for the MRUI quantitation package. MAGMA. 12: 141–152. [DOI] [PubMed] [Google Scholar]
- 20. Stefan D., Di Cesare F., Andrasescu A., Popa E., Lazariev A., Vescovo E., Strbak O., Williams S., Starcuk Z., Cabanas M., et al. . 2009. Quantitation of magnetic resonance spectroscopy signals: the jMRUI software package. Meas. Sci. Technol. 20: 104035. [Google Scholar]
- 21. Vanhamme L., Van Den Boogaart A., and Van Huffel S.. 1997. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J. Magn. Reson. 129: 35–43. [DOI] [PubMed] [Google Scholar]
- 22. Boesch C., Machann J., Vermathen P., and Schick F.. 2006. Role of proton MR for the study of muscle lipid metabolism. NMR Biomed. 19: 968–988. [DOI] [PubMed] [Google Scholar]
- 23. Vermathen P., Boesch C., and Kreis R.. 2003. Mapping fiber orientation in human muscle by proton MR spectroscopic imaging. Magn. Reson. Med. 49: 424–432. [DOI] [PubMed] [Google Scholar]
- 24. Szczepaniak L. S., Babcock E. E., Schick F., Dobbins R. L., Garg A., Burns D. K., Denis Mcgarry J., Stein D. T., and Denis McGarry J.. 1999. Measurement of intracellular triglyceride stores by 1H spectroscopy: validation in vivo. Am. J. Physiol. Endocrinol. Metab. 276: E977–E989. [DOI] [PubMed] [Google Scholar]
- 25. Krssák M., Roden M., Mlynárik V., Meyerspeer M., and Moser E.. 2004. 1H NMR relaxation times of skeletal muscle metabolites at 3 T. MAGMA. 16: 155–159. [DOI] [PubMed] [Google Scholar]
- 26. Brage S., Brage N., Ekelund U., Luan J., Franks P. W., Froberg K., and Wareham N. J.. 2006. Effect of combined movement and heart rate monitor placement on physical activity estimates during treadmill locomotion and free-living. Eur. J. Appl. Physiol. 96: 517–524. [DOI] [PubMed] [Google Scholar]
- 27. Tanaka H., Monahan K. D., and Seals D. R.. 2001. Age-predicted maximal heart rate revisited. J. Am. Coll. Cardiol. 37: 153–156. [DOI] [PubMed] [Google Scholar]
- 28. Payne F., Lim K., Girousse A., Brown R. J., Kory N., Robbins A., Xue Y., Sleigh A., Cochran E., Adams C., et al. . 2014. Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease. Proc. Natl. Acad. Sci. USA. 111: 8901–8906. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Bergman B. C., Perreault L., Hunerdosse D. M., Koehler M. C., Samek A. M., and Eckel R. H.. 2010. Increased intramuscular lipid synthesis and low saturation relate to insulin sensitivity in endurance-trained athletes. J. Appl. Physiol. 108: 1134–1141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. van Hees A. M. J., Jans A., Hul G. B., Roche H. M., Saris W. H. M., and Blaak E. E.. 2011. Skeletal muscle fatty acid handling in insulin resistant men. Obesity (Silver Spring). 19: 1350–1359. [DOI] [PubMed] [Google Scholar]
- 31. Perreault L., Bergman B. C., Hunerdosse D. M., and Eckel R. H.. 2010. Altered intramuscular lipid metabolism relates to diminished insulin action in men, but not women, in progression to diabetes. Obesity (Silver Spring). 18: 2093–2100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Petersen K. F., Oral E. A., Dufour S., Befroy D., Ariyan C., Yu C., Cline G. W., DePaoli A. M., Taylor S. I., Gorden P., et al. . 2002. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J. Clin. Invest. 109: 1345–1350. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Brechtel K., Jacob S., Machann J., Hauer B., Nielsen M., Meissner H. P., Matthaei S., Haering H. U., Claussen C. D., and Schick F.. 2000. Acquired generalized lipoatrophy (AGL): highly selective MR lipid imaging and localized 1H-MRS. J. Magn. Reson. Imaging. 12: 306–310. [DOI] [PubMed] [Google Scholar]
- 34. Gemmink A., Daemen S., Brouwers B., Huntjens P. R., Schaart G., Moonen-Kornips E., Jörgensen J., Hoeks J., Schrauwen P., and Hesselink M. K. C.. 2018. Dissociation of intramyocellular lipid storage and insulin resistance in trained athletes and type 2 diabetes patients; involvement of perilipin 5? J. Physiol. 596: 857–868. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Amati F., Dubé J. J., Alvarez-Carnero E., Edreira M. M., Chomentowski P., Coen P. M., Switzer G. E., Bickel P. E., Stefanovic-Racic M., Toledo F. G. S., et al. . 2011. Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin resistance: another paradox in endurance-trained athletes? Diabetes. 60: 2588–2597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Russell A. P., Gastaldi G., Bobbioni-Harsch E., Arboit P., Gobelet C., Dériaz O., Golay A., Witztum J. L., and Giacobino J-P.. 2003. Lipid peroxidation in skeletal muscle of obese as compared to endurance-trained humans: a case of good vs. bad lipids? FEBS Lett. 551: 104–106. [DOI] [PubMed] [Google Scholar]
- 37. Décombaz J., Schmitt B., Ith M., Decarli B., Diem P., Kreis R., Hoppeler H., and Boesch C.. 2001. Postexercise fat intake repletes intramyocellular lipids but no faster in trained than in sedentary subjects. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281: R760–R769. [DOI] [PubMed] [Google Scholar]
- 38. Klepochová R., Valkovič L., Hochwartner T., Triska C., Bachl N., Tschan H., Trattnig S., Krebs M., and Krššák M.. 2018. Differences in muscle metabolism between triathletes and normally active volunteers investigated using multinuclear magnetic resonance spectroscopy at 7T. Front. Physiol. 9: 300. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39. Bruce C. R., Anderson M. J., Carey A. L., Newman D. G., Bonen A., Kriketos A. D., Cooney G. J., and Hawley J. A.. 2003. Muscle oxidative capacity is a better predictor of insulin sensitivity than lipid status. J. Clin. Endocrinol. Metab. 88: 5444–5451. [DOI] [PubMed] [Google Scholar]
- 40. Bergman B. C., Perreault L., Strauss A., Bacon S., Kerege A., Harrison K., Brozinick J. T., Hunerdosse D. M., Playdon M. C., Holmes W., et al. . 2018. Intramuscular triglyceride synthesis: importance in muscle lipid partitioning in humans. Am. J. Physiol. Endocrinol. Metab. 314: E152–E164. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Howald H., Boesch C., Kreis R., Matter S., Billeter R., Essen-Gustavsson B., and Hoppeler H.. 2002. Content of intramyocellular lipids derived by electron microscopy, biochemical assays, and 1H-MR spectroscopy. J. Appl. Physiol. 92: 2264–2272. [DOI] [PubMed] [Google Scholar]
- 42. Ith M., Huber P. M., Egger A., Schmid J-P., Kreis R., Christ E., and Boesch C.. 2010. Standardized protocol for a depletion of intramyocellular lipids (IMCL). NMR Biomed. 23: 532–538. [DOI] [PubMed] [Google Scholar]
- 43. Manco M., Mingrone G., Greco A. V., Capristo E., Gniuli D., De Gaetano A., and Gasbarrini G.. 2000. Insulin resistance directly correlates with increased saturated fatty acids in skeletal muscle triglycerides. Metabolism. 49: 220–224. [DOI] [PubMed] [Google Scholar]
- 44. Muoio D. M. 2010. Intramuscular triacylglycerol and insulin resistance: Guilty as charged or wrongly accused? Biochim. Biophys. Acta. 1801: 281–288. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.